194 related articles for article (PubMed ID: 37694560)
21. Clinical efficacy of amrubicin in patients with small cell lung cancer relapse after first-line treatment including immune checkpoint inhibitors: A retrospective multicenter study (TOPGAN 2021-01).
Uematsu S; Kitazono S; Tanaka H; Saito R; Kawashima Y; Ohyanagi F; Tozuka T; Ryosuke T; Sakatani T; Horiike A; Yoshizawa T; Saiki M; Tambo Y; Koyama J; Kanazu M; Kudo K; Tsuchiya-Kawano Y; Yanagitani N; Nishio M
Thorac Cancer; 2023 Jan; 14(2):168-176. PubMed ID: 36408699
[TBL] [Abstract][Full Text] [Related]
22. Immune checkpoint inhibitor therapy in a patient with small cell lung cancer and anti-transcriptional intermediary factor 1-γ antibody-positive dermatomyositis: A case report.
Kim Y; Park D; Choi SY; Chung C
Thorac Cancer; 2022 Oct; 13(19):2808-2811. PubMed ID: 35982637
[TBL] [Abstract][Full Text] [Related]
23. Survival, Chemotherapy Treatments, and Health Care Utilization Among Patients with Advanced Small Cell Lung Cancer: An Observational Study.
He J; Shao C; Hui SL; Zhang Z; Baker J; Dexter PR; Kachroo S; Jin F
Adv Ther; 2020 Jan; 37(1):552-565. PubMed ID: 31828610
[TBL] [Abstract][Full Text] [Related]
24. Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensive-stage small cell lung cancer: a retrospective study.
Chen Q; Li Y; Zhang W; Wang C; Yang S; Guo Q
J Cancer Res Clin Oncol; 2022 Feb; 148(2):401-408. PubMed ID: 34797416
[TBL] [Abstract][Full Text] [Related]
25. Recent advances and future strategies in first-line treatment of ES-SCLC.
Gomez-Randulfe I; Leporati R; Gupta B; Liu S; Califano R
Eur J Cancer; 2024 Mar; 200():113581. PubMed ID: 38301317
[TBL] [Abstract][Full Text] [Related]
26. CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy.
Lai AY; Sorrentino JA; Dragnev KH; Weiss JM; Owonikoko TK; Rytlewski JA; Hood J; Yang Z; Malik RK; Strum JC; Roberts PJ
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33004541
[TBL] [Abstract][Full Text] [Related]
27. Long-term outcomes in extensive disease small cell lung cancer patients treated without immune checkpoint inhibitors.
Wakuda K; Yabe M; Kodama H; Nishioka N; Miyawaki T; Miyawaki E; Mamesaya N; Kobayashi H; Omori S; Ono A; Kenmotsu H; Naito T; Murakami H; Shimizu T; Gon Y; Takahashi T
Jpn J Clin Oncol; 2021 Dec; 51(12):1736-1743. PubMed ID: 34642738
[TBL] [Abstract][Full Text] [Related]
28. Clinical impact of first-line PD-1 or PD-L1 inhibitors combined with chemotherapy in extensive-stage small cell lung cancer patients: A real-world multicenter propensity score-matched study.
Xie J; Chen M; Han H; Xu K; Qiu G; Lin X; Song Y; Ye J; Lv T; Zhan P
Thorac Cancer; 2023 May; 14(15):1327-1338. PubMed ID: 37005095
[TBL] [Abstract][Full Text] [Related]
29. Current state of the art and future perspectives with immunotherapy in the management of small cell lung cancer.
Rijavec E; Genova C; Biello F; Rossi G; Indini A; Grossi F
Expert Rev Respir Med; 2021 Nov; 15(11):1427-1435. PubMed ID: 34590937
[TBL] [Abstract][Full Text] [Related]
30. Real-world burden of chemotherapy-induced myelosuppression in patients with small cell lung cancer: a retrospective analysis of electronic medical data from community cancer care providers.
Epstein RS; Weerasinghe RK; Parrish AS; Krenitsky J; Sanborn RE; Salimi T
J Med Econ; 2022; 25(1):108-118. PubMed ID: 34927520
[TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of immunohistochemical classification utilizing biopsy specimens in patients with extensive-disease small-cell lung cancer treated with first-line chemotherapy and immune checkpoint inhibitors.
Shijubou N; Sumi T; Kubo T; Sasaki K; Tsukahara T; Kanaseki T; Murata K; Keira Y; Terai K; Ikeda T; Yamada Y; Chiba H; Hirohashi Y; Torigoe T
J Cancer Res Clin Oncol; 2024 Mar; 150(3):125. PubMed ID: 38483588
[TBL] [Abstract][Full Text] [Related]
32. Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma.
Talukder R; Makrakis D; Lin GI; Diamantopoulos LN; Dawsey S; Gupta S; Carril-Ajuria L; Castellano D; de Kouchkovsky I; Jindal T; Koshkin VS; Park JJ; Alva A; Bilen MA; Stewart TF; McKay RR; Tripathi N; Agarwal N; Vather-Wu N; Zakharia Y; Morales-Barrera R; Devitt ME; Cortellini A; Fulgenzi CAM; Pinato DJ; Nelson A; Hoimes CJ; Gupta K; Gartrell BA; Sankin A; Tripathi A; Zakopoulou R; Bamias A; Murgic J; Fröbe A; Rodriguez-Vida A; Drakaki A; Liu S; Lu E; Kumar V; Lorenzo GD; Joshi M; Isaacsson-Velho P; Buznego LA; Duran I; Moses M; Barata P; Sonpavde G; Wright JL; Yu EY; Montgomery RB; Hsieh AC; Grivas P; Khaki AR
Clin Genitourin Cancer; 2022 Dec; 20(6):558-567. PubMed ID: 36155169
[TBL] [Abstract][Full Text] [Related]
33. Emerging drugs for small cell lung cancer: a focused review on immune checkpoint inhibitors.
Reddy HG; Qin A; Kalemkerian GP
Expert Opin Emerg Drugs; 2020 Sep; 25(3):353-366. PubMed ID: 32683991
[TBL] [Abstract][Full Text] [Related]
34. Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer.
Shao J; Wang C; Ren P; Jiang Y; Tian P; Li W
Biosci Rep; 2020 May; 40(5):. PubMed ID: 32315071
[TBL] [Abstract][Full Text] [Related]
35. PD-L1 inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real-world evidence.
Huang L; Chen S; Liu H; Meng L; Liu C; Wu X; Wang Y; Luo S; Tu H; Wang C; Zhang M; Gong X
Cancer Med; 2024 Apr; 13(7):e7125. PubMed ID: 38613182
[TBL] [Abstract][Full Text] [Related]
36. Current status and future perspectives of immune checkpoint inhibitors in extensive-stage small cell lung cancer.
Liu X; Xing H; Liu B
Am J Cancer Res; 2022; 12(6):2447-2464. PubMed ID: 35812062
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of the combination of immunotherapy and chemotherapy for extensive-stage small-cell lung cancer: a systematic review.
Wang T; Li Y; Zheng X
BMC Health Serv Res; 2023 Jun; 23(1):691. PubMed ID: 37365540
[TBL] [Abstract][Full Text] [Related]
38. FRESC: French Real world Extensive stage SCLC Cohorts: A retrospective study on patient characteristics and treatment strategy based on KBP-2010.
Debieuvre D; Dayen C; Dixmier A; Pau D; Sibley-Revelat A; Greenwood W; Gally S; Falchero L
Lung Cancer; 2022 Feb; 164():1-7. PubMed ID: 34954472
[TBL] [Abstract][Full Text] [Related]
39. Prospective Observational Study Evaluating the Prognostic Value of the G8 Screening Tool for Extensive-Stage Small Cell Lung Cancer Patients Who Received Programmed Death-Ligand 1 Inhibitor plus Platinum-Etoposide Chemotherapy.
Morimoto K; Yamada T; Takeda T; Shiotsu S; Date K; Harada T; Tamiya N; Chihara Y; Takemura Y; Yamada T; Kanda H; Ishida M; Yoshimura A; Iwasaku M; Tokuda S; Kim YH; Takayama K
Drugs Aging; 2023 Jun; 40(6):563-571. PubMed ID: 37145245
[TBL] [Abstract][Full Text] [Related]
40. Survival outcomes associated with corticosteroid use before chemoimmunotherapy in patients with advanced lung cancer.
Sorial MN; Huynh JP; Azzoli CG; Liauw JC; Brunault RD; Collins CM; Zullo AR
Eur J Cancer; 2021 Mar; 145():234-244. PubMed ID: 33431285
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
